肿瘤相关成纤维细胞在子宫内膜癌中的研究进展

doi:10.12280/gjfckx.20220617

摘要/Abstract

摘要：

肿瘤微环境（tumor microenvironment，TME）中不同类型细胞的相互作用在子宫内膜癌（endometrial cancer）的发生、发展中起到了关键作用。其中肿瘤相关成纤维细胞（cancer-associated fibroblasts，CAFs）作为TME的重要组成部分，通过直接或间接作用的方式调控子宫内膜癌细胞的恶性生物学行为，促进肿瘤进展。研究表明CAFs参与调节子宫内膜癌细胞的增殖、迁移、侵袭和代谢等途径，同时在TME的基质重塑、血管生成和免疫调节等方面发挥着重要作用。以CAFs为靶点的临床试验研究打破了子宫内膜癌传统治疗手段的局限性，为终末期子宫内膜癌患者带来了新的治疗选择，然而仅有部分患者获益，其中CAFs的来源及功能异质性与治疗抵抗密切相关。综述CAFs在子宫内膜癌中的研究进展，以深入了解CAFs的特性及功能，为子宫内膜癌的诊治提供新的思路。

Abstract:

The interaction of different types of cells in the tumor microenvironment(TME) plays a key role in the development of endometrial cancer. Among them, cancer-associated fibroblasts (CAFs), as an important component of TME, regulate the malignant bilolgical behavior of endometrial cancer through direct or indirect ways, and promote tumor progression. Studies have shown that CAFs are involved in regulating the pathways of proliferation, migration, invasion and metabolism of endometrial cancer cells, and they also play an important role in the matrix remodeling, angiogenesis and immune regulation of TME. Clinical trials targeting CAFs have broken the limitations of traditional treatments for endometrial cancer and brought new treatment options for patients with end-stage endometrial cancer, but only some patients will benefit. The sources and functional heterogeneity of CAFs are closely related to treatment resistance. This article reviews the research progress of CAFs in endometrial cancer to deeply understand the characteristics and functions of CAFs, so as to provide new ideas for the treatment of endometrial cancer.

Key words: Endometrial neoplasms, Cancer-associated fibroblasts, Tumor microenvironment, Neovascularization, pathologic, Therapy

余志成, 汪宏波. 肿瘤相关成纤维细胞在子宫内膜癌中的研究进展[J]. 国际妇产科学杂志, 2023, 50(1): 16-19.

YU Zhi-cheng, WANG Hong-bo. Reseach Progress of Cancer-Associated Fibroblasts in Endometrial Cancer[J]. Journal of International Obstetrics and Gynecology, 2023, 50(1): 16-19.

参考文献 36

[1]	Lu KH, Broaddus RR. Endometrial Cancer[J]. N Engl J Med, 2020, 383(21):2053-2064. doi: 10.1056/NEJMra1514010. doi: 10.1056/NEJMra1514010
[2]	Chen Y, McAndrews KM, Kalluri R. Clinical and therapeutic relevance of cancer-associated fibroblasts[J]. Nat Rev Clin Oncol, 2021, 18(12):792-804. doi: 10.1038/s41571-021-00546-5. doi: 10.1038/s41571-021-00546-5 pmid: 34489603
[3]	Subramaniam KS, Tham ST, Mohamed Z, et al. Cancer-associated fibroblasts promote proliferation of endometrial cancer cells[J]. PLoS One, 2013, 8(7):e68923. doi: 10.1371/journal.pone.0068923. doi: 10.1371/journal.pone.0068923
[4]	Li BL, Lu W, Qu JJ, et al. Loss of exosomal miR-148b from cancer-associated fibroblasts promotes endometrial cancer cell invasion and cancer metastasis[J]. J Cell Physiol, 2019, 234(3):2943-2953. doi: 10.1002/jcp.27111. doi: 10.1002/jcp.27111
[5]	Desbois M, Wang Y. Cancer-associated fibroblasts: Key players in shaping the tumor immune microenvironment[J]. Immunol Rev, 2021, 302(1):241-258. doi: 10.1111/imr.12982. doi: 10.1111/imr.12982 pmid: 34075584
[6]	Jena BC, Das CK, Bharadwaj D, et al. Cancer associated fibroblast mediated chemoresistance: A paradigm shift in understanding the mechanism of tumor progression[J]. Biochim Biophys Acta Rev Cancer, 2020, 1874(2): 188416. doi: 10.1016/j.bbcan.2020.188416. doi: 10.1016/j.bbcan.2020.188416
[7]	Biffi G, Tuveson DA. Diversity and Biology of Cancer-Associated Fibroblasts[J]. Physiol Rev, 2021, 101(1):147-176. doi: 10.1152/physrev.00048.2019. doi: 10.1152/physrev.00048.2019
[8]	Yu Z, Zhang J, Zhang Q, et al. Single-cell sequencing reveals the heterogeneity and intratumoral crosstalk in human endometrial cancer[J]. Cell Prolif, 2022, 55(6):e13249. doi: 10.1111/cpr.13249. doi: 10.1111/cpr.13249
[9]	Voon YC, Omar IS, Wu MH, et al. Cancer-associated fibroblasts as cellular vehicles in endometrial cancer cell migration[J]. Oncol Lett, 2022, 23(1):3. doi: 10.3892/ol.2021.13121. doi: 10.3892/ol.2021.13121 pmid: 34820002
[10]	Subramaniam KS, Omar IS, Kwong SC, et al. Cancer-associated fibroblasts promote endometrial cancer growth via activation of interleukin-6/STAT-3/c-Myc pathway[J]. Am J Cancer Res, 2016, 6(2):200-213. pmid: 27186396
[11]	Teng F, Tian WY, Wang YM, et al. Cancer-associated fibroblasts promote the progression of endometrial cancer via the SDF-1/CXCR4 axis[J]. J Hematol Oncol, 2016, 9:8. doi: 10.1186/s13045-015-0231-4. doi: 10.1186/s13045-015-0231-4
[12]	Wang X, Zhang W, Sun X, et al. Cancer-associated fibroblasts induce epithelial-mesenchymal transition through secreted cytokines in endometrial cancer cells[J]. Oncol Lett, 2018, 15(4):5694-5702. doi: 10.3892/ol.2018.8000. doi: 10.3892/ol.2018.8000 pmid: 29563996
[13]	Zhang N, Wang Y, Liu H, et al. Extracellular vesicle encapsulated microRNA-320a inhibits endometrial cancer by suppression of the HIF1α/VEGFA axis[J]. Exp Cell Res, 2020, 394(2):112113. doi: 10.1016/j.yexcr.2020.112113. doi: 10.1016/j.yexcr.2020.112113
[14]	王国珍. 间质细胞外泌体miR-136在子宫内膜癌发生发展中的作用研究[D]. 武汉: 华中科技大学, 2019.
[15]	Fan JT, Zhou ZY, Luo YL, et al. Exosomal lncRNA NEAT1 from cancer-associated fibroblasts facilitates endometrial cancer progression via miR-26a/b-5p-mediated STAT3/YKL-40 signaling pathway[J]. Neoplasia, 2021, 23(7):692-703. doi: 10.1016/j.neo.2021.05.004. doi: 10.1016/j.neo.2021.05.004
[16]	Yoshida S, Asanoma K, Yagi H, et al. Fibronectin mediates activation of stromal fibroblasts by SPARC in endometrial cancer cells[J]. BMC Cancer, 2021, 21(1):156. doi: 10.1186/s12885-021-07875-9. doi: 10.1186/s12885-021-07875-9 pmid: 33579227
[17]	Yamamoto M, Kaizaki Y, Kogami A, et al. Prognostic significance of tumor budding, poorly differentiated cluster, and desmoplastic reaction in endometrioid endometrial carcinomas[J]. J Obstet Gynaecol Res, 2021, 47(11):3958-3967. doi: 10.1111/jog.14997. doi: 10.1111/jog.14997
[18]	Wei S, Conner MG, Zhang K, et al. Juxtatumoral stromal reactions in uterine endometrioid adenocarcinoma and their prognostic significance[J]. Int J Gynecol Pathol, 2010, 29(6):562-567. doi: 10.1097/PGP.0b013e3181e36321. doi: 10.1097/PGP.0b013e3181e36321 pmid: 20881855
[19]	Mochizuki S, Ao T, Sugiura T, et al. Expression and Function of a Disintegrin and Metalloproteinases in Cancer-Associated Fibroblasts of Colorectal Cancer[J]. Digestion, 2020, 101(1):18-24. doi: 10.1159/000504087. doi: 10.1159/000504087 pmid: 31722362
[20]	Nicolas-Boluda A, Vaquero J, Vimeux L, et al. Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment[J]. Elife, 2021, 10:e58688. doi: 10.7554/eLife.58688. doi: 10.7554/eLife.58688
[21]	Inoue T, Adachi K, Kawana K, et al. Cancer-associated fibroblast suppresses killing activity of natural killer cells through downregulation of poliovirus receptor (PVR/CD155), a ligand of activating NK receptor[J]. Int J Oncol, 2016, 49(4):1297-1304. doi: 10.3892/ijo.2016.3631. doi: 10.3892/ijo.2016.3631 pmid: 27499237
[22]	Mariathasan S, Turley SJ, Nickles D, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells[J]. Nature, 2018, 554(7693):544-548. doi: 10.1038/nature25501. doi: 10.1038/nature25501
[23]	Reijnen C, van Weelden WJ, Arts M, et al. Poor outcome in hypoxic endometrial carcinoma is related to vascular density[J]. Br J Cancer, 2019, 120(11):1037-1044. doi: 10.1038/s41416-019-0461-2. doi: 10.1038/s41416-019-0461-2
[24]	李美艳, 韩新彦, 王菊荣, 等. 子宫内膜癌中VM、Leptin、VEGF的表达及与临床特征的关系[J]. 新疆医科大学学报, 2018, 41(9):1107-1110,1116. doi: 10.3969/j.issn.1009-5551.2018.09.013. doi: 10.3969/j.issn.1009-5551.2018.09.013
[25]	梁军, 苗蕊, 邢慧敏. 血管生成拟态在子宫内膜癌组织中的表达及意义[J]. 中国肿瘤临床, 2015, 42(23):1124-1127. doi: 10.3969/j.issn.1000-8179.2015.23.050. doi: 10.3969/j.issn.1000-8179.2015.23.050
[26]	Yu H, Wang H, Qie A, et al. FGF13 enhances resistance to platinum drugs by regulating hCTR1 and ATP7A via a microtubule-stabilizing effect[J]. Cancer Sci, 2021, 112(11):4655-4668. doi: 10.1111/cas.15137. doi: 10.1111/cas.15137
[27]	Janzen DM, Rosales MA, Paik DY, et al. Progesterone receptor signaling in the microenvironment of endometrial cancer influences its response to hormonal therapy[J]. Cancer Res, 2013, 73(15):4697-4710. doi: 10.1158/0008-5472.CAN-13-0930. doi: 10.1158/0008-5472.CAN-13-0930 pmid: 23744837
[28]	Byron SA, Loch DC, Pollock PM. Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells[J]. Int J Gynecol Cancer, 2012, 22(9):1517-1526. doi: 10.1097/IGC.0b013e31826f6806. doi: 10.1097/IGC.0b013e31826f6806 pmid: 23060048
[29]	Eritja N, Domingo M, Dosil MA, et al. Combinatorial therapy using dovitinib and ICI182.780 (fulvestrant) blocks tumoral activity of endometrial cancer cells[J]. Mol Cancer Ther, 2014, 13(4):776-787. doi: 10.1158/1535-7163.MCT-13-0794. doi: 10.1158/1535-7163.MCT-13-0794 pmid: 24448819
[30]	Sootome H, Fujita H, Ito K, et al. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors[J]. Cancer Res, 2020, 80(22):4986-4997. doi: 10.1158/0008-5472.CAN-19-2568. doi: 10.1158/0008-5472.CAN-19-2568 pmid: 32973082
[31]	Harding TC, Long L, Palencia S, et al. Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer[J]. Sci Transl Med, 2013, 5(178):178ra39. doi: 10.1126/scitranslmed.3005414. doi: 10.1126/scitranslmed.3005414
[32]	Chan JK, Deng W, Higgins RV, et al. A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study[J]. Gynecol Oncol, 2017, 146(3):554-559. doi: 10.1016/j.ygyno.2017.05.033. doi: S0090-8258(17)30889-2 pmid: 28728751
[33]	Bender D, Sill MW, Lankes HA, et al. A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study[J]. Gynecol Oncol, 2015, 138(3):507-512. doi: 10.1016/j.ygyno.2015.07.018. doi: 10.1016/j.ygyno.2015.07.018 pmid: 26186911
[34]	Dizon DS, Sill MW, Schilder JM, et al. A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study[J]. Gynecol Oncol, 2014, 135(3):441-445. doi: 10.1016/j.ygyno.2014.10.001. doi: 10.1016/j.ygyno.2014.10.001 pmid: 25312396
[35]	Meng X, Dizon DS, Yang S, et al. Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53[J]. Obstet Gynecol Int, 2013, 2013:828165. doi: 10.1155/2013/828165. doi: 10.1155/2013/828165
[36]	Makker V, Colombo N, Casado Herráez A, et al. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer[J]. N Engl J Med, 2022, 386(5):437-448. doi: 10.1056/NEJMoa2108330. doi: 10.1056/NEJMoa2108330